AstraZeneca Plc is making significant moves in the weight-loss industry by agreeing to pay CSPC Pharmaceutical Group Ltd. up to $18.5 billion for a promising lineup of obesity drug candidates.
This deal involves an upfront payment of $1.2 billion for eight drug candidates, which feature four injectable therapies designed to tackle obesity and related health issues.
According to Chief Executive Officer Pascal Soriot, AstraZeneca aims to introduce more affordable weight-loss medications that are easier to administer while better preserving muscle mass compared to existing treatments. The company is simultaneously boosting its investments in China, pledging $15 billion through 2030 during UK Prime Minister Keir Starmer’s visit this week.
In early trading in London, AstraZeneca shares fell by 1 percent, although they experienced a nearly 30 percent increase in 2025. Meanwhile, CSPC’s stock plunged by 13 percent in Hong Kong, as analysts noted potential profit-taking following the announcement.
The agreement grants AstraZeneca rights to CSPC’s most advanced candidate, SYH2082, which is on the brink of human trials and acts on the same gut hormones as Eli Lilly & Co.’s successful Zepbound.
Additionally, the partnership provides Astra with access to CSPC’s innovative long-acting peptide technology that could facilitate monthly dosing, a crucial focus as pharmaceutical companies compete to develop the next wave of weight-loss solutions. Current leading products from Lilly and Novo Nordisk A/S are both administered weekly.
Sharon Barr, Astra’s executive vice president and head of biopharmaceuticals R&D, highlighted a significant challenge with existing injectable GLP-1 therapies, pointing out that patient adherence can drop to as low as 27 percent within a year. This often results in high discontinuation rates, despite patients initially achieving their desired outcomes.
For injectable peptides, such as Novo’s Wegovy, offering less frequent doses could serve as a key differentiator for individuals committed to maintaining weight loss, Barr stated.
Prioritizing convenience through less frequent injections is a critical strategy for companies aiming to penetrate the market. Competitors like Amgen Inc. are also developing a monthly injection named MariTide, while Pfizer Inc. is working on a long-acting formulation acquired through its Metsera Inc. acquisition last year.
AstraZeneca has previously licensed an obesity pill from Chinese biotech Eccogene, alongside developing a drug targeting amylin and another injectable aimed at both GLP-1 and glucagon, a hormone responsible for regulating blood sugar levels.
CSPC stands to gain up to $3.5 billion in development and regulatory milestones, as well as potential sales milestone payments of up to $13.8 billion.
